About

Antimicrobial resistance (AMR) is spreading globally, threatening our ability to treat common infectious diseases, resulting in prolonged illness, disability, and death. The AMR problem is particularly relevant to low- and middle-income countries, endangering our achievement of the Sustainable Development Goals.

Many recent initiatives to fight AMR focus, however, on developed countries. AMR-Global achieves a true global focus, bringing together science and business in the fight against AMR, via prevention and infection control, access to improved diagnostics, and antimicrobial stewardship, and access to effective antimicrobial drugs and vaccines.

AMR-Global represents public and private parties from the Netherlands and beyond. Together we work on our vision: a world where everybody has access to effective antimicrobial drugs and vaccines. To ensure that the innovations will become widely and quickly available for all those in need, AMR-Global tackles obstacles that stand in the way of the ambitions of our members.

The Netherlands belongs to the global frontrunners in the fight against AMR, as evidenced by the low prevalence of resistant infections in the country. We believe the Netherlands can and should take the lead help other countries to take a similar lead position. To do so, we need a strong and internationally oriented public private collaboration can bring viable and necessary solutions for AMR to the market. This is precisely what AMR-Global is about.

The key objectives that follow from this mission are:
  1. Testing interventions in a real-world setting
  2. Gaining a better understanding of the drivers of the global AMR problem
  3. Creating a stronger climate for innovative strategies and products
  4. Overcoming issues of market failure
  5. Promoting an interdisciplinary and cross-sectional approach towards the development of new technologies
  6. Ensuring equitable, faster and better access to all those is need
  7. Focusing on prevention and sustainable use
  8. Speak a clear language about drug-resistant infections, so that people understand what drug-resistant infections are, that they are not limited to one illness or country, and that this is not a problem of the future but that they are affecting us today

Examples of problems that AMR-GLOBAL will adress

AMR-Global unites leading public and private partners in the fights against AMR

AMR-GLOBAL is a starting international public private partnership with roots in the Netherlands.

We are currently writing our strategy 2020-2025.

Our current member list is as follows:
The Amsterdam Institute for Global Health and Development (AIGHD) is an international research and education institute that works to develop sustainable solutions to major health problems. AIGHD was initiated as a partnership between the Amsterdam University Medical Centers (AUMC), the University of Amsterdam (UvA) and the Vrije Universiteit Amsterdam (VU). AIGHD is a dynamic research and education institute that thrives on intense collaboration among experts from multiple disciplines including biomedicine, economics and social and behavioral sciences. With its interdisciplinary and translational approach, AIGHD addresses the most critical medical, social, economic and political challenges in global health and development that cut across national and political borders. www.aighd.org
Madam Therapeutics’ is a privately held company from the Netherlands that is developing Synthetic Anti-Microbial and Anti-Biofilm Peptides (SAAPs) to combat resistant bacterial infections. Our SAAPs are highly active against such bacteria and have a very favorable tolerance profile. Our SAAPs combine two characteristics essential for such new strategies: powerful killing of bacteria and limited likelihood of emerging resistance. https://madam-therapeutics.com/
Levels Diagnostics developsa Rapid Diagnostic Test that allows healthcare professionals can distinguish a bacterial infection from other forms of infectious diseases, using just one drop of blood, drawn by a simple finger-prick. The disposable RDT can be described as a small hand-held ‘lab-on-a-chip’ and will perform a simple diagnosis within minutes. The medical healthcare professional can easily interpret the results and confirm the bacterial/viral infection. https://levels.bio/
Topicus connects people, healthcare professionals, providers, commissioners and financiers with digital health solutions. Our aim is to contribute towards a (better) balanced healthcare system by people and patient empowerment, community engagement and operational excellence according to the quadruple aim. We 1) involve the patient in their own care process with blended care and smart technology; 2) optimize collaboration between https://topicus.nl/
Sphereon develops AI and Blockchain technology for software developers for building applications in the field of health care, education and governments. https://sphereon.com/
VitalFluid is a company specialized in the development of customer driven Plasma Activated Water applications to contribute to the sustainability goals of our customers and society. With this technology, residues of medicines but also multi resistant microorganisms are broken down by plasma, and the overall toxicity the waste water is reduced significantly. https://vitalfluid.nl/
KWR generates knowledge to enable the water sector to operate water-wisely in our urbanised society. At KWR, we have a sense of professional and social responsibility for the quality of water. Our scientific findings and the resulting practical innovations contribute, worldwide, to a sustainable water provision in the urban watercycle. Research in the field of AMR aims at improving our understanding of the underlying mechanisms. By combining chemical and microbiological analyses, the relationship between occurrence of antibiotics and potential metabolites and antimicrobial resistance genes in waste- and receiving waters will become clear. KWR contributes to AMR-GLOBAL to help answering fundamental questions about and monitor of the spreading of antibiotic resistance. https://www.kwrwater.nl/
KNCV Tuberculosis Foundation was established 116 years ago and works in over 20 countries in Africa, Asia and Eastern Europe. We have led several international AMR initiatives and are known for programmatic interventions to prevent and address resistance to TB medicines in the context of broader health systems strengthening. These interventions include the introduction of new drugs and regimens; rapid laboratory methods to detect resistance; AMR stewardship; pharmacovigilance; policy development; training and advocacy. https://kncvtbc.org/en
Shan-X is currently developing a platform for providing fast drug resistance testing and aims to deliver fast and accurate diagnosis at the primary care https://shanxmedtech.nl/
Deltares is an independent institute for applied research in the field of water and subsurface. Throughout the world, we work on smart solutions, innovations and applications for people, environment and society. Our main focus is on deltas, coastal regions and river basins. We combine laboratory and field studies with software models to predict how the various substances including antibiotics spread through the water system, surface waters and groundwater. This makes it possible to assess risks in the future and to predict the effect of interventions. https://deltares.nl

Latest News

News from AMR-Global partners
See more news

Team

The strategic direction of AMR-GLOBAL is currently being discussed withIN a steering group. The members of the steering group are:
Constance Schultsz
Constance Schultsz

Executive Board member, AIGHD, Professor of Global Health, Department of Global Health, Amsterdam UMC, University of Amsterdam.

    Remko van Leeuwen
    Remko van Leeuwen

    CEO and founder Madam Therapeutics, Board member BEAM Alliance, program Director HOOKVAC group for Affordable Vaccines

    Ronald Zwartkruis
    Ronald Zwartkruis

    International partnership lead Public Health at Topicus Healthcare

      Maarten Boender
      Maarten Boender

      Product Owner & Product Manager for Sphereon and Vice Chairman Blockchain Innovation Foundation

        Coen Breedveld
        Coen Breedveld

        Co-founder Levels

          Kitty van Weezenbeek
          Kitty van Weezenbeek

          Executive Director at KNCV Tuberculosis Foundation

            Luc Hornstra
            Luc Hornstra

            Scientific researcher microbiology at KWR Watercycle Research Institute

              Upcoming AMR Events

              There are no upcoming events at this time.